SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced ...
Fig. 1: Different drug release profile depending on the linker used for block-copolymers of nano-micellesFR-JQ1H/m with aliphatic aldehyde linker: Fast drug release in gradually elevated ...
Barcelona, Spain: Researchers have found that a drug that targets the key, cancer-causing gene, MYC, has for the first time been able to inhibit the function of the gene in a phase I clinical trial.
A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional ...
So, what insight are we left with? “On the highest level,” notes Dr. Eisenman, “this study really demonstrates that a single amino acid substitution in a single protein is enough to predispose the ...
Pancreatic cancer may evade the immune system using a clever molecular trick. Researchers found that the cancer-driving protein MYC also suppresses immune alarm signals, allowing tumors to grow ...
Please provide your email address to receive an email when new articles are posted on . Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results